These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34254203)

  • 1. Longitudinal monitor of Jun N-terminal kinase pathway associated phosphatase reflects clinical efficacy to triple conventional disease-modifying anti-rheumatic drugs treatment in rheumatoid arthritis patients.
    Song D; Zhu X; Wang F; Sun J
    Inflammopharmacology; 2021 Aug; 29(4):1131-1138. PubMed ID: 34254203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JKAP correlates with lower disease risk and inflammation, and its increment during etanercept treatment associates with commendable treatment efficiency in rheumatoid arthritis patients.
    Mou XY; Jin D; Zhang Q; Guan JT; Jin Y
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2654-2661. PubMed ID: 33829452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JNK pathway-associated phosphatase associates with rheumatoid arthritis risk, disease activity, and its longitudinal elevation relates to etanercept treatment response.
    Sun L; Tu J; Chen X; Dai M; Xia X; Liu C; Zhou Y
    J Clin Lab Anal; 2021 Apr; 35(4):e23709. PubMed ID: 33547838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort.
    Geng Y; Han J; Deng X; Zhang Z
    Clin Rheumatol; 2014 Aug; 33(8):1061-6. PubMed ID: 24777468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JNK pathway-associated phosphatase illustrates low expression and negative correlations with inflammation, disease activity, and T-helper 17 cells in inflammatory bowel disease children.
    Wang C; Bai C; Mao C; Leng X; Wang F; Guo X
    J Clin Lab Anal; 2022 Sep; 36(9):e24488. PubMed ID: 35908771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sustained intensive therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis: a 5-year real-world consecutive study.
    Cai YM; Li R; Ye H; He J; Sun XL; Jin JY; Liu JJ; Gan YZ; You XJ; Xu J; Shi LJ; Cheng G; Wang QW; Li ZG
    Chin Med J (Engl); 2020 Jun; 133(12):1397-1403. PubMed ID: 32496302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(2):e001050. PubMed ID: 31908842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
    Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
    Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum CDC42 is increased during tumor necrosis factor inhibitor treatment, and its elevation correlates with satisfactory treatment response in rheumatoid arthritis patients.
    Yang Y; Wu B; Tian P; Huang L
    Int J Rheum Dis; 2023 Aug; 26(8):1521-1528. PubMed ID: 37382403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).
    Ramiro S; Landewé RB; van der Heijde D; Sepriano A; FitzGerald O; Ostergaard M; Homik J; Elkayam O; Thorne JC; Larche M; Ferraccioli G; Backhaus M; Boire G; Combe B; Schaeverbeke T; Saraux A; Dougados M; Rossini M; Govoni M; Sinigaglia L; Cantagrel AG; Allaart CF; Barnabe C; Bingham CO; Tak PP; van Schaardenburg D; Hammer HB; Dadashova R; Hutchings E; Paschke J; Maksymowych WP
    Ann Rheum Dis; 2020 Apr; 79(4):453-459. PubMed ID: 32094157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors for low disease activity and remission in rheumatoid arthritis patients treated with biological DMARDs.
    Wacharapornin P; Suwannalai P
    J Med Assoc Thai; 2014 Nov; 97(11):1157-63. PubMed ID: 25675680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of feet and ankle arthritis and their impact on clinical indices in patients with rheumatoid arthritis: a cross-sectional study.
    Lee SW; Kim SY; Chang SH
    BMC Musculoskelet Disord; 2019 Sep; 20(1):420. PubMed ID: 31506089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
    Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
    Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JNK Pathway-Associated Phosphatase as a Serum Marker for Disease Activity and Treatment Outcome of Juvenile Idiopathic Arthritis.
    Zhu S; Lv H; Luo Y; Huang Q; Shen J
    Tohoku J Exp Med; 2021 Jan; 253(1):19-28. PubMed ID: 33441511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing remission in rheumatoid arthritis patients: results from Karnataka rheumatoid arthritis comorbidity (KRAC) study.
    Chandrashekara S; Shobha V; Dharmanand BG; Jois R; Kumar S; Mahendranath KM; Haridas V; Prasad S; Singh Y; Daware MA; Swamy A; Subramanian R; Somashekar SA; Shanthappa AM; Anupama KR
    Int J Rheum Dis; 2018 Nov; 21(11):1977-1985. PubMed ID: 27452347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics.
    Osiri M; Wongpiyabovorn J; Sattayasomboon Y; Thammacharoenrach N
    Clin Rheumatol; 2016 Jul; 35(7):1673-81. PubMed ID: 27188857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of radiographic joint damage in rheumatoid arthritis patients in DAS28 remission using single- or combined with methotrexate non biological disease-modifying antirheumatic drug therapy in routine clinical practice.
    Katayama K; Okubo T; Sato T; Ito H; Fukai R; Baba H
    Mod Rheumatol; 2015 Jan; 25(1):50-5. PubMed ID: 24983407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs.
    Arias de la Rosa I; Escudero-Contreras A; Ruiz-Ponce M; Román-Rodríguez C; Pérez-Sánchez C; Ábalos-Aguilera MDC; Ortega-Castro R; Alcaide J; Murri M; Font P; Calvo-Gutiérrez J; Luque-Tevar M; Patiño-Trives AM; Guzmán-Ruiz R; Malagón MDM; Tinahones FJ; Collantes-Estévez E; López-Pedrera C; Barbarroja N
    Front Immunol; 2021; 12():744022. PubMed ID: 34721412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.